PFE.N
Latest Trade
35.12USDChange
-0.10(-0.27%)Volume
3,477,443Today's Range
-
35.4252 Week Range
-
43.22As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 35.21 |
|---|---|
Open | 35.34 |
Volume | 3,477,443 |
3M AVG Volume | 585.66 |
Today's High | 35.42 |
Today's Low | 34.88 |
52 Week High | 43.22 |
52 Week Low | 27.89 |
Shares Out (MIL) | 5,554.83 |
Market Cap (MIL) | 187,920.00 |
Forward P/E | 11.75 |
Dividend (Yield %) | 4.49 |
Pfizer, BioNtech Granted FDA Fast Track Status For Two COVID-19 Vaccine Candidates
Viiv Healthcare Gives Positive Data From Study On How Best To Integrate Investigational Once-Monthly Injectable HIV Treatment In U.S. Healthcare
FDA Approves Avelumab For Urothelial Carcinoma Maintenance Treatment
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Industry
Biotechnology & Drugs
Executive Leadership
Albert Bourla
Chairman of the Board, Chief Executive Officer
John D. Young
Chief Business Officer, Group President
Frank A. D'Amelio
Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Angela Hwang
Group President, Pfizer Biopharmaceuticals Group
Dawn Rogers
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM) | 12.36 |
|---|---|
Price To Sales (TTM) | 3.71 |
Price To Book (MRQ) | 2.89 |
Price To Cash Flow (TTM) | 8.87 |
Total Debt To Equity (MRQ) | 80.41 |
LT Debt To Equity (MRQ) | 55.79 |
Return on Investment (TTM) | 12.02 |
Return on Equity (TTM) | 9.63 |
Pfizer Inc and partner BioNTech SE said on Monday two of their experimental coronavirus vaccines received 'fast track' designation from the U.S. health agency, speeding up the regulatory review process.
Two experimental coronavirus vaccines by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer have received the U.S. Food and Drug Administration's 'fast track' designation, the companies said on Monday.
BioNTech SE and Pfizer Inc's COVID-19 vaccine candidate is expected to be ready to seek regulatory approval by the end of 2020, the Wall Street Journal reported on Friday, citing the German biotech firm's chief executive officer.
BioNTech SE and Pfizer Inc's COVID-19 vaccine candidate is expected to be ready to seek regulatory approval by the end of 2020, the Wall Street Journal reported on Friday, citing the German biotech firm's chief executive officer.
* PFIZER INC - PLEDGED $100 MILLION TO NEW ANTIMICROBIAL RESISTANCE ACTION FUND Source text for Eikon: Further company coverage:
* MISSION THERAPEUTICS SAYS RAISES $15 MILLION AND EXPANDS ITS RELATIONSHIP WITH PFIZER
* Risky assets start second half of year on high note * Brazil manufacturing returns to growth in June * BioNTech, Pfizer's COVID-19 vaccine shows potential (Updates prices, adds comments, bullets) By Ambar Warrick and Shreyashi Sanyal July 1 (Reuters) - Brazil's real shot...
A COVID-19 vaccine developed by German biotech firm BioNTech <BNTX.O> and U.S. pharmaceutical giant Pfizer <PFE.N> has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.
A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.
* BIOINVENT EXTENDS RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH PFIZER INC.
* FDA APPROVES BAVENCIO AS FIRST-LINE MAINTENANCE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
* CHOBANI, PFIZER AND SAP JOIN RUNNING LIST OF COMPANIES PULLING FACEBOOK ADS - CNBC Source text: https://cnb.cx/2ZmlRGL
* SETS QUARTERLY CASH DIVIDEND OF $0.38PER SHARE Source text for Eikon: Further company coverage:
* APTEVO THERAPEUTICS - WILL RECEIVE ROYALTY PAYMENTS FROM PFIZER RELATED TO SALES OF A RITUXIMAB BIOSIMILAR PRODUCT, RUXIENCE
* PFIZER ANNOUNCES START OF FOUR PHASE 3 CLINICAL TRIALS FOR INVESTIGATIONAL VACCINES
Pfizer Inc and Sangamo Therapeutics Inc said on Thursday their gene therapy helped maintain levels of a vital protein for up to 14 months in patients with a rare genetic disorder in which blood does not clot easily.
* MERCK AND PFIZER’S SGLT2 INHIBITOR STEGLATROTM (ERTUGLIFLOZIN) MEETS PRIMARY ENDPOINT IN VERTIS CV TRIAL FOR PATIENTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
-- Source link: https://bloom.bg/2ULqtV4
* PUMA BIOTECHNOLOGY - ON JUNE 8 CO ENTERED INTO A LETTER AGREEMENT WITH PFIZER RELATING TO LICENSE AGREEMENT, ORIGINALLY DATED AUGUST 18, 2011
* FDA APPROVES PFIZER’S ONCOLOGY SUPPORTIVE CARE BIOSIMILAR, NYVEPRIA™ (PEGFILGRASTIM-APGF)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.